VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals
Skyharbour's Partner Company Mustang Energy Commences Field Program at 914W Uranium Project Located in the Athabasca Basin, Saskatchewan
Bold Ventures Announces Increase and Extension of Non-Brokered Private Placement and Closing of Third Tranche, and Signs Agreement with Investor News Network
